9 active not recruiting, 7 terminated, 4 withdrawn, 2 no longer available. 22 Phase 1, 7 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 22 | Active not recruiting 9, Terminated 6, Withdrawn 4, Completed 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 7 | Terminated 5, Active not recruiting 2 |
| Phase 3 | 1 | Terminated 1 |
Follow Rimiducid: new trials by email Literature Review of Rimiducid trials Research Report on Rimiducid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells, Trastuzumab deruxtecan (T-DXd), Rimiducid - Breast Cancer | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2026-10-01 | 2026-08-19 |
| A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE) P-CD19CD20-ALLO1 Cells, Cyclophosphamide, Fludarabine - Systemic Lupus Erythematosus | Phase 1 | Withdrawn | Genentech, Inc. | 2026-06-30 | 2026-08-05 | |
| P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies P-CD19CD20-ALLO1, Rimiducid - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma | Phase 1 | Active not recruiting | Poseida Therapeutics, Inc. | 120 | 2024-04-16 | 2026-05-07 |
| Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate - Solid Tumors | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 54 | 2023-10-24 | 2026-10-06 |
| P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma P-BCMA-ALLO1 CAR-T cells, Rimiducid, Methotrexate - Multiple Myeloma | Phase 1 | Active not recruiting | Poseida Therapeutics, Inc. | 275 | 2022-05-05 | 2026-04-24 |
| P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors P-MUC1C-ALLO1 CAR-T cells, Rimiducid - Breast Cancer, Ovarian Cancer | Phase 1 | Active not recruiting | Poseida Therapeutics, Inc. | 180 | 2022-02-15 | 2026-02-09 |
| P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) P-PSMA-101 CAR-T cells, Rimiducid - Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type | Phase 1 | Terminated | Poseida Therapeutics, Inc. | 40 | 2020-02-28 | 2025-02-17 |
| Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Rivogenlecleucel, Rimiducid - Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2020-01-02 | 2020-08-14 | |
| T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma Cyclophosphamide, Fludarabine, Rimiducid - Myeloma-Multiple, Myeloma, Plasma-Cell | Phase 1 | Completed | National Cancer Institute (NCI) | 13 | 2019-06-13 | 2021-09-09 |
| Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma iC9-CAR19 T cells, Bendamustine, Fludarabine - Lymphoma, Lymphoma, B-Cell | Phase 1 | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 12 | 2019-03-12 | 2026-07-31 |
| Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS rivogenlecleucel, rimiducid, Cyclophosphamide - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 / Phase 3 | Terminated | Bellicum Pharmaceuticals | 1 | 2018-12-27 | 2023-09-29 |
| Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant BPX-501 T cells, rimiducid - Hematologic Malignancy | Phase 1 | Active not recruiting | Bellicum Pharmaceuticals | 15 | 2018-02-01 | 2022-07-12 |
| P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) P-BCMA-101 CAR-T cells, Rimiducid - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Poseida Therapeutics, Inc. | 105 | 2017-09-20 | 2024-03-28 |
| Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma BPX-701, Rimiducid - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Terminated | Bellicum Pharmaceuticals | 4 | 2017-04-14 | 2023-10-05 |
| Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study Rimiducid, rivogenlecleucel - Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child | Phase 1 / Phase 2 | Terminated | Bellicum Pharmaceuticals | 187 | 2017-01-01 | 2023-09-26 |
| Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors BPX-601, Rimiducid - Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer | Phase 1 | Terminated | Regeneron Pharmaceuticals | 52 | 2016-11-30 | 2026-02-23 |
| Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies BPX-501, AP1903 - Hematologic Malignancies | Phase 1 | Withdrawn | Bellicum Pharmaceuticals | 2016-07-01 | 2020-10-05 | |
| Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant BPX-501, Rimiducid - Leukemia, Myelodysplastic Syndromes | Phase 1 | Active not recruiting | Bellicum Pharmaceuticals | 10 | 2016-07-01 | 2022-07-12 |
| Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT rivogenlecleucel, Rimiducid - Leukemia, Myelodysplastic Syndromes | Phase 1 | Withdrawn | Bellicum Pharmaceuticals | 2016-05-01 | 2020-10-05 | |
| Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant BPX-501 T cells, Rimiducid - Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child | Phase 1 / Phase 2 | Active not recruiting | Bellicum Pharmaceuticals | 120 | 2014-04-01 | 2022-07-12 |
Showing 20 of 25. Sign in to see all of them.
Myelodysplastic Syndromes (11) · Leukemia (8) · Leukemia, Myeloid, Acute (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Hematologic Neoplasms (7) · Lymphoma (5) · Multiple Myeloma (5) · Lymphoma, Non-Hodgkin (4) · Anemia, Aplastic (3) · Cytopenia (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Primary Immunodeficiency Diseases (3) · Anemia (2) · Anemia, Diamond-Blackfan (2)
Bellicum Pharmaceuticals (11) · Poseida Therapeutics, Inc. (5) · UNC Lineberger Comprehensive Cancer Center (3) · M.D. Anderson Cancer Center (2) · Fred Hutchinson Cancer Center (1) · Genentech, Inc. (1) · National Cancer Institute (NCI) (1) · Regeneron Pharmaceuticals (1)
United States (21) · Italy (3) · United Kingdom (1)
Rajesh Belani, M.D. (2) · Bora Lim, MD (1) · Ecaterina Dumbrava, M D (1) · Elizabeth Krakow (1) · James N Kochenderfer, M.D. (1) · Maika Onishi, M.D. (1) · Matthew Foster, MD (1) · Natalie Grover, MD (1) · Natalie S Grover, MD (1) · Simon Heidegger, M.D. (1) · Simon Heidegger, MD (1)
PMID 31215818, PMID 39737899, PMID 40443562, PMID 41285709
K12CA120780 (1), P30CA015704 (1)